Equities

Harmony Biosciences Holdings Inc

HRMY:NMQ

Harmony Biosciences Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)38.83
  • Today's Change-0.16 / -0.41%
  • Shares traded249.82k
  • 1 Year change+3.96%
  • Beta0.7134
Data delayed at least 15 minutes, as of Sep 20 2024 19:34 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments353323234
Total Receivables, Net745535
Total Inventory5.364.304.43
Prepaid expenses139.357.64
Other current assets, total5.548.793.22
Total current assets451400284
Property, plant & equipment, net2.722.890.82
Goodwill, net------
Intangibles, net137161144
Long term investments7223--
Note receivable - long term------
Other long term assets3.950.493.52
Total assets811674433
LIABILITIES
Accounts payable183.791.00
Accrued expenses1257349
Notes payable/short-term debt000
Current portion long-term debt/capital leases152.002.00
Other current liabilities, total6.370.011.36
Total current liabilities1647954
Total long term debt179190190
Total debt194192192
Deferred income tax------
Minority interest------
Other liabilities, total2.112.503.18
Total liabilities344271247
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital610675640
Retained earnings (accumulated deficit)(143)(272)(454)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.00(0.15)--
Total equity467403187
Total liabilities & shareholders' equity811674433
Total common shares outstanding576059
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.